The immune system is designed to discriminate between self and tumor tissue. Through
genetic recombination, there is fundamentally no limit to the number of tumor antigens that …

US7018632B2 - Method for ex vivo immunization using heterologous intact bispecific and/or
trispecific antibodies - Google Patents US7018632B2 - Method for ex vivo immunization using …

A valuable resource for researchers and workers in the fields of both pharmaceuticals and
biotechnology as well as undergraduates in biochemistry, applied biology, biomedical …

Bispecific antibodies have been exploited both as cancer immunodiagnostics and as cancer
therapeutics, and have shown promise in several clinical trials in cancer imaging and …

Bispecific antibodies (BiAbs) offer a unique opportunity to redirect immune effector cells to
kill cancer cells. BiAbs combine the benefits of different binding specificities of two …

After adoptive transfer of pre‐activated lymphocytes into the operation cavity of glioma
patients, tumor regression and improved survival have been reported in some patients …

The use of anti-CD3× antitumor bispecific Abs is an attractive and highly specific approach
in cancer therapy. Recombinant Ab technology now provides powerful tools to enhance the …

Background Redirection of T lymphocytes against tumor antigens can induce dramatic
regression of advanced stage malignancy. The use of bispecific antibodies (BsAbs) that bind …

The bispecific monoclonal antibody (biMAb) OC/TR combines the anti‐ovarian‐cancer
reactivity of the MOv18 monoclonal antibody (MAb) with the reactivity of an anti‐CD3 MAb …

Bispecific antibodies (bsAbs) are molecules that simultaneously bind two different antigens
(Ags). bsAbs represent a very active field in tumor immunotherapy with more than one …